Resistell Revenue and Competitors
Estimated Revenue & Valuation
- Resistell's estimated annual revenue is currently $10.3M per year.
- Resistell's estimated revenue per employee is $251,000
Employee Data
- Resistell has 41 Employees.
- Resistell grew their employee count by 8% last year.
Resistell's People
| Name | Title | Email/Phone |
|---|
Resistell Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is Resistell?
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.
keywords:N/A
N/A
Total Funding
41
Number of Employees
$10.3M
Revenue (est)
8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Resistell News
... HiMedia Laboratories, Alifax Holding S.p.A., Creative Diagnostics, Resistell AG, Danaher Corporation, Becton, Dickinson and Company,...
... Alifax Holding, Creative Diagnostics, Resistell AG, Danaher Corporation, Becton, Dickinson and Company, Thermo Fisher Scientific,...
Other Companies in Muttenz
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 71 | 20% | N/A |
#2 | N/A | 103 | 21% | N/A |
#3 | $17.1M | 118 | 34% | N/A |